Latest filing published 18 Feb 2026 for Penumbra Inc. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Thomas Wilder (board member) discloses dealings in 2 companies, chiefly Penumbra Inc and Endologix Inc /DE/. Between 2 June 2016 and 13 February 2026, the trades on record add up to 42 filings.
No open-market purchase appears, only 28 sales worth €870k. Other entries cover 14 share grants. So far in 2026, the count stands at no purchases and 1 sale.
Most recently, on 18 February 2026, the filings show a share grant in Penumbra Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
17 of 17 declarations